Wells says generic Apriso competition may come much sooner than Valeant expectedAfter the U.S. Patent Office's Trials and Appeal Board ruled that patents related to Valeant's Apriso were unpatentable, Wells Fargo analyst David Maris said the decision may allow generic competition to the ulcerative colitis drug a "dozen years" earlier than Valeant anticipated. Valeant's 2016 10-K does not list Apriso as one of products the company sees facing generic competition between 2017 and 2021, noted Maris, who adds that it is possible that Valeant appeals the PTAB decision. Maris keeps an Underperform rating on Valeant shares. |